Barry Greene was President and Chief Executive Officer of Sage Therapeutics from 2020 until its acquisition by Supernus Pharmaceuticals in 2025.

Before joining Sage, Mr. Greene spent 17 years at Alnylam Pharmaceuticals, serving as Chief Operating Officer and then President of the company. Prior to Alnylam, Mr. Greene was the General Manager of Oncology at Millennium Pharmaceuticals (subsequently acquired by Takeda Pharmaceutical Company), where he led global strategy and execution for its oncology business, culminating in the successful U.S. Food and Drug Administration approval and launch of VELCADE® (bortezomib). Prior to joining Millennium, Mr. Greene served as Executive Vice President and Chief Business Officer for Mediconsult.com. Earlier in his career, he served as Vice President of Marketing and Customer Services and Vice President of Strategic Integration at AstraZeneca and Partner at Andersen Consulting.  

Mr. Greene currently serves on the board of directors of Karyopharm Therapeutics and Dyne Therapeutics. He received his B.S. in Industrial Engineering from the University of Pittsburgh and completed the Senior Scholars executive program at Duke University’s Medical School and Fuqua School of Business.